Intended for healthcare professionals

  1. Education
  2. A living WHO guideline...
  3. A living WHO guideline on drugs to prevent covid-19
Practice Rapid Recommendations

A living WHO guideline on drugs to prevent covid-19

BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n526 (Published 02 March 2021) Cite this as: BMJ 2021;372:n526
Visual summary of recommendation Last updated 24 Mar 2023
Interventions Population This recommendation applies only to people with these characteristics: People who do not have covid-19 Hydroxychloroquine Recommendation against (strong) Tixagevimab-cilgavimab Recommendation against (conditional)

Hydroxychloroquine

Recommendation 1No interventionHydroxychloroquineorPeople who do not havecovid-19We recommend not usinghydroxychloroquine to prevent covid-19StrongAll or nearly all informed people would likelywant the intervention to the left. Benefitswould outweigh harms for almost everyoneWeakMost people would likely want the interventionto the left. Benefits would outweigh harms forthe majority, but not for everyoneWeakMost people would likely want the interventionto the right. Benefits would outweigh harmsfor the majority, but not for everyoneStrongAll or nearly all informed people would likelywant the intervention to the right. Benefitswould outweigh harms for almost everyone

Evidence profile

Favours no interventionFavours hydroxychloroquineNo important differenceThe panel found that this difference was not important for most patients,because the intervention effects were negligible and/or very imprecise, forexample confidence intervals that include both important benefit and harm
Evidence qualityEvents per 1000 people

Mortality No important difference33HighMore

Based on data from 6822 patients in 7 studiesHydroxychloroquine has little or noeffect on mortalityHighGRADE rating,because of:Risk of biasNo serious concernsImprecisionNo serious concernsIndirectnessNo serious concernsInconsistencyNo serious concernsPublication biasNo serious concernsGRADE certainty ratingsHighThe authors have a lot ofconfidence that the trueeffect is similar to theestimated effectModerateThe authors believe thatthe true effect is probablyclose to theestimated effectLowThe true effect might bemarkedly different fromthe estimated effectVery lowThe true effect isprobably markedlydifferent from theestimated effect

Admission to hospital No important difference31HighMore

Based on data from 7432 patients in 10 studiesHydroxychloroquine has little or noeffect on hospital admissionHighGRADE rating,because of:Risk of biasNo serious concernsImprecisionNo serious concernsIndirectnessNo serious concernsInconsistencyNo serious concernsPublication biasNo serious concernsGRADE certainty ratingsHighThe authors have a lot ofconfidence that the trueeffect is similar to theestimated effectModerateThe authors believe thatthe true effect is probablyclose to theestimated effectLowThe true effect might bemarkedly different fromthe estimated effectVery lowThe true effect isprobably markedlydifferent from theestimated effect

Lab confirmed SARS-CoV-2 No important difference6259HighMore

Based on data from 8379 patients in 12 studiesHydroxychloroquine has little or noeffect on laboratory confirmedSARS-CoV-2 infectionHighGRADE rating,because of:Risk of biasNo serious concernsImprecisionNo serious concernsIndirectnessNo serious concernsInconsistencyNo serious concernsPublication biasNo serious concernsGRADE certainty ratingsHighThe authors have a lot ofconfidence that the trueeffect is similar to theestimated effectModerateThe authors believe thatthe true effect is probablyclose to theestimated effectLowThe true effect might bemarkedly different fromthe estimated effectVery lowThe true effect isprobably markedlydifferent from theestimated effect

Adverse events6 fewer2228HighMore

Based on data from 6153 patients in 9 studiesHydroxychloroquine has a smallincrease in adverse effects leading todiscontinuationHighGRADE rating,because of:Risk of biasNo serious concernsImprecisionNo serious concernsIndirectnessNo serious concernsInconsistencyNo serious concernsPublication biasNo serious concernsGRADE certainty ratingsHighThe authors have a lot ofconfidence that the trueeffect is similar to theestimated effectModerateThe authors believe thatthe true effect is probablyclose to theestimated effectLowThe true effect might bemarkedly different fromthe estimated effectVery lowThe true effect isprobably markedlydifferent from theestimated effect
See all outcomes

Individual considerations

The panel inferred that almost all well informed patients would not want to receive hydroxychloroquine given there are probably no positive effects and there was a risk of adverse events. The panel did not expect there would be much variation in values and preferences between patients for this intervention Values and preferences

Tixagevimab-cilgavimab

Recommendation 1No interventionTixagevimab-cilgavimaborPeople who do not havecovid-19We suggest not using tixagevimab-cilgavimab to prevent covid-19StrongAll or nearly all informed people would likelywant the intervention to the left. Benefitswould outweigh harms for almost everyoneWeakMost people would likely want the interventionto the left. Benefits would outweigh harms forthe majority, but not for everyoneWeakMost people would likely want the interventionto the right. Benefits would outweigh harmsfor the majority, but not for everyoneStrongAll or nearly all informed people would likelywant the intervention to the right. Benefitswould outweigh harms for almost everyone

Individual considerations

The panel reviewed in vitro evidence reducing the applicability of available trial data; while prophylactic use demonstrated modest reduction in laboratory-confirmed symptomatic covid-19, lack of in vitro neutralisation of new SARS-CoV-2 sub-lineages was considered to have rendered these results obsolete Justification Conditions for use of treatment The panel inferred that, in the absence of compelling evidence of clinical effectiveness for the currently circulating SARS-CoV-2 sublineages, the majority of informed individuals would not choose to receive tixagevimab-cilgavimab Values and preferences Any prophylactic use of this intervention should be restricted to extremely vulnerable individuals, and patients presenting a sublineage that is neutralised in-vitro Typical characteristics of extremely vulnerable individuals include: People highly unlikely to mount an immune response following covid-19 vaccination People at increased risk of developing severe manifestations of covid-19 because of limited physiological reserve

©BMJ Publishing Group Limited.

Disclaimer: This infographic is not a validated clinical decision aid. This information is provided without any representations, conditions or warranties that it is accurate or up to date. BMJ and its licensors assume no responsibility for any aspect of treatment administered with the aid of this information. Any reliance placed on this information is strictly at the user's own risk. For the full disclaimer wording see BMJ's terms and conditions: https://www.bmj.com/company/legal-information/

Find recommendations, evidence summaries and consultation decision aids for use in your practice

Linked Research

Prophylaxis against covid-19

Please note that it may take up to 5 days for the peer review documents to appear.

For research papers The BMJ has fully open peer review. This means that accepted research papers published from early 2015 onwards usually have their prepublication history posted alongside them on bmj.com.

This prepublication history comprises all previous versions of the manuscript, the study protocol (submitting the protocol is mandatory for all clinical trials and encouraged for all other studies at The BMJ), the report from the manuscript committee meeting, the reviewers’ comments, and the authors’ responses to all the comments from reviewers and editors.

In rare instances we determine after careful consideration that we should not make certain portions of the prepublication record publicly available. For example, in cases of stigmatised illnesses we seek to protect the confidentiality of reviewers who have these illnesses. In other instances there may be legal or regulatory considerations that make it inadvisable or impermissible to make available certain parts of the prepublication record.

In all instances in which we have determined that elements of the prepublication record should not be made publicly available, we expect that authors will respect these decisions and also will not share this information.

Back to top